Sixth Wave (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) recently provided an update on its patent-pending Accelerated Molecularly Imprinted Polymer (“AMIPs(TM)”) technology relative to SARS-CoV-2 variants, in particular, B.1.1.529 (“Omicron”). As previously announced, the AMIPS platform was proven capable of detecting all variants of interest tested to date. According to the update, screening against the Omicron variant will commence as soon as virus samples are available at the La Ki Shing Institute of virology, SIXW’s testing partner. The identification of yet another variant with suspected properties more transmissible and potentially dangerous than previous generations strongly indicates that COVID-19 will be around for a long time and that swift, affordable and highly-accurate testing regimes must become the norm. SIXW continues to maintain rapid development of its AMIPs technology and expects completion of the next development phase in the coming weeks, with a successful outcome leading to validation testing by third party laboratories.
To view the full press release, visit https://ibn.fm/8seYb
About Sixth Wave Innovations Inc.
Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (“MIPs”). The company is in the process of a commercial rollout of its Affinity(TM) cannabinoid purification system, as well as IXOS(R), a line of extraction polymers for the gold mining industry. The company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (“AMIPs(TM)”) label. Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines and other pathogens, for which the company has products at various stages of development. For more information about Sixth Wave, please visit the company’s website at www.SixthWave.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
